ARTICLE | Clinical News
Cerevel's GABA A modulator reduces photosensitivity in epilepsy patients
April 11, 2019 8:49 PM UTC
After spinning out of Pfizer in October to develop the pharma's discontinued neuroscience pipeline, Cerevel plans to begin by year end another Phase II trial of CVL-865 in broader epilepsy populations.
Cerevel Therapeutics LLC (Boston, Mass.) announced the next trial as data published in Neurology showed that CVL-865 significantly reduced photosensitivity in a Phase IIa trial to treat patients with photosensitive epilepsy. CVL-865 (formerly PF-06372865) is a GABA A receptor α 2 (GABRA2), GABRA3 and GABRA5 positive allosteric modulator...